NPPA sets ceiling price of Dextrose Injection

Three manufacturers of Dextrose (Glucose) Injection (25% w/v) include Otsuka Pharmaceutical India, Denis Chem Lab and Rusoma Laboratories.

This came in line with the Wholesale Price Index (WPI) data provided by the Office of the Economic Advisor, Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry whereby the annual change in the WPI works out as 10.76607% during the calendar year 2021 over the corresponding period in 2020.

Dextrose belongs to a class of drugs called Glucose-Elevating Agents. Dextrose Injection is a sterile, nonpyrogenic solution for fluid replenishment and caloric supply in single-dose containers for intravenous administration. It contains no antimicrobial agents.

It is a sterile solution used to provide your body with extra water and carbohydrates (calories from sugar). It is used when a patient is not able to drink enough liquids or when additional fluids are needed.

Dextrose is used to treat very low blood sugar (hypoglycemia), frequently in people with diabetes mellitus. It is also given by injection to treat insulin shock.

In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11 and paragraph 14 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22nd March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 3939(E) dated 23.09.2021 and S.O. 5428(E) dated 28.12.2021, in so far as they relate to Dextrose (Glucose) Injection (25% w/v) in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features like (i) self-collapsibility and self-sealeability (ii) not having air-vent and (iii) there is no chance of contamination during manufacture/ infusion/ admixing levels mentioned in the Table A herein below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, has revised the price based on Wholesale price index(WPI) of 2021 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of goods and services tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form andstrength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof

The notification further added;

(a) The ceiling prices are applicable with effect from 01.04.2022 (ceiling prices are inclusive of Wholesale Price Index (WPI) @10.76607% for the year 2021 over 2020).

(b) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled formulations at price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any

To view the official notice, click the link below:

https://www.nppaindia.nic.in/wp-content/uploads/2022/03/1506E_Dextro_Eng.pdf